Kamada Ltd.

KMDA Healthcare Drug Manufacturers Specialty & Generic

Kamada Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $180.5 million, up 12.1% from fiscal 2024. In the quarter to June 2026, revenue grew 22.7%, EPS grew 23.1%, free cash flow grew 165.7% and total debt fell 38.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

7.77 0.06 −0.77%
Market cap
$451.7M
P/E
20.4×
Fwd P/E
0.0×
Dividend yield
5.41%
F-score
7/9
Altman Z
3.33
Beneish M
−2.35
Dividend safety
50/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
8.40% 7.97% 7.64% 7.86%

+8 more TTM periods

Piotroski F-Score
7 7 7 7
ROA
5.92% 5.37% 5.38% 5.61%
ROIC
8.47% 8.06% 8.06% 8.51%
Return on Tangible Assets
11.49% 11.26% 10.80% 11.17%
Average Days of Receivables
80.98 81.67 66.06 73.77
Free Cash Flow per Share
0.45 0.28 0.27 0.31
Free Cash Flow
26.32 16.36 15.65 18.34
Capital Expenditures
(9.44) (9.35) (9.84) (9.99)
Other line items
Cash ROIC
7.61% 4.77% 4.42% 5.27%
Accounts Receivable Turnover
4.93 4.87 6.04 6.22
Accounts Payable Turnover
3.05 2.35 2.86 3.44
Inventory Turnover
1.34 1.31 1.27 1.25
Average Days of Payables
130.78 160.01 124.00 127.41
Days of Inventory on Hand
279.29 291.69 297.97 317.10
Tax Rate
(0.17) (0.08) (0.14) (0.04)
Research and Development Expense of Revenue
5.17% 6.02% 7.20% 7.31%
Selling, General and Administrative Expense of Revenue
21.15% 21.17% 20.60% 20.22%
Share Based Compensation of Revenue
1.09% 0.81% 0.47% 0.32%
Interest Coverage
26.79 29.52 30.36 34.96
Operating CF/Net income
1.61 1.26 1.26 1.39
Depreciation/Fixed assets
0.35 0.37 0.36 0.40
Capex/Depreciation
(0.62) (0.62) (0.66) (0.66)
Revenue per Share
3.31 3.08 3.13 2.97
Operating CF per Share
0.62 0.44 0.44 0.48
Capex per Share
(0.16) (0.16) (0.17) (0.17)
Capex to Sales
0.05 0.05 0.05 0.06

Fold the line items

Columns are period end dates